MA30075B1 - Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale - Google Patents
Derives de pyrimidine pour le traitement d'une croissance cellulaire anormaleInfo
- Publication number
- MA30075B1 MA30075B1 MA31059A MA31059A MA30075B1 MA 30075 B1 MA30075 B1 MA 30075B1 MA 31059 A MA31059 A MA 31059A MA 31059 A MA31059 A MA 31059A MA 30075 B1 MA30075 B1 MA 30075B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- cell growth
- abnormal cell
- pyrimidine derivatives
- mammals
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title abstract 3
- 230000010261 cell growth Effects 0.000 title abstract 3
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale La présente invention concerne un composé de formule (I), ou un de ses sels pharmaceutiquement acceptables, formule dans laquelle Ar représente un groupe de formule (III), et R1, R2, R13, A, K, M, L1, L2, X, Y1, Y2, Q, un de ses sels, où R1, R2, R13, A, K, L1, L2, W, X, Z1, Z2, Y1, Y2, Z1, Z2, M, Q, W, X, m, p et q répondent aux définitions figurant dans le présent mémoire. Ces dérivés de pyrimidine nouveaux sont utiles dans le traitement d'une croissance cellulaire anormale, telle qu'un cancer, chez des mammifères. La présente invention concerne également une méthode d'utilisation de ces composés dans le traitement d'une croissance cellulaire anormale chez des mammifères, notamment des êtres humains, et des compositions pharmaceutiques contenant ces composés.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75270805P | 2005-12-21 | 2005-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30075B1 true MA30075B1 (fr) | 2008-12-01 |
Family
ID=38038639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31059A MA30075B1 (fr) | 2005-12-21 | 2008-06-20 | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7820648B2 (fr) |
| EP (1) | EP1966207A2 (fr) |
| JP (1) | JP4332590B2 (fr) |
| KR (1) | KR101060051B1 (fr) |
| CN (1) | CN101346380B (fr) |
| AP (1) | AP2008004488A0 (fr) |
| AR (1) | AR058399A1 (fr) |
| AU (1) | AU2006327871A1 (fr) |
| BR (1) | BRPI0620324A2 (fr) |
| CA (1) | CA2634646C (fr) |
| CR (1) | CR10095A (fr) |
| DO (1) | DOP2006000289A (fr) |
| EA (1) | EA014551B1 (fr) |
| EC (1) | ECSP088563A (fr) |
| GT (1) | GT200600517A (fr) |
| HN (1) | HN2006042221A (fr) |
| IL (1) | IL191555A0 (fr) |
| MA (1) | MA30075B1 (fr) |
| ME (1) | MEP0908A (fr) |
| NL (1) | NL2000375C2 (fr) |
| NO (1) | NO20082338L (fr) |
| PE (1) | PE20071138A1 (fr) |
| RS (1) | RS20080272A (fr) |
| SV (1) | SV2008002969A (fr) |
| TN (1) | TNSN08270A1 (fr) |
| TW (1) | TW200736258A (fr) |
| UA (1) | UA89123C2 (fr) |
| UY (1) | UY30051A1 (fr) |
| WO (1) | WO2007072158A2 (fr) |
| ZA (1) | ZA200804488B (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53109B (sr) | 2003-07-30 | 2014-06-30 | Rigel Pharmaceuticals Inc. | Jedinjenja 2,4 pirimidindiamina za upotrebu u tretmanu ili prevenciji autoimunih bolesti |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| JP2009542604A (ja) * | 2006-07-06 | 2009-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ４−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用 |
| MX2009004426A (es) * | 2006-10-23 | 2009-08-12 | Cephalon Inc | Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. |
| NZ580372A (en) * | 2007-04-18 | 2012-01-12 | Pfizer Prod Inc | Pyrimidine and triazine derivatives including a sulfonamide group for the treatment of abnormal cell growth such as cancer |
| CN101903357A (zh) * | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | 作为pkc抑制剂的环状胺取代的嘧啶二胺 |
| CA2707653A1 (fr) * | 2007-12-03 | 2009-06-11 | Boehringer Ingelheim International Gmbh | Nouveaux composes |
| UY31714A (es) * | 2008-03-20 | 2009-11-10 | Boehringer Ingelheim Int | Preparación selectiva de pirimidinas sustituidas |
| CA2718858A1 (fr) * | 2008-03-20 | 2009-09-24 | Boehringer Ingelheim International Gmbh | Elaboration regioselective de pyrimidines substituees |
| EA020807B1 (ru) | 2008-06-17 | 2015-01-30 | Астразенека Аб | Соединения пиридина |
| EP2161259A1 (fr) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-haloalkyle-diaminopyrimidines substitués |
| US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
| TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| US8729265B2 (en) | 2009-08-14 | 2014-05-20 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
| US8466155B2 (en) * | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
| TWI513694B (zh) | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
| US8927547B2 (en) | 2010-05-21 | 2015-01-06 | Noviga Research Ab | Pyrimidine derivatives |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| PT2646448T (pt) | 2010-11-29 | 2017-10-04 | Osi Pharmaceuticals Llc | Inibidores macrocíclicos de cinases |
| US9006241B2 (en) | 2011-03-24 | 2015-04-14 | Noviga Research Ab | Pyrimidine derivatives |
| RU2586333C1 (ru) | 2011-12-09 | 2016-06-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные 4-гидрокси-1,2,3,4-тетрагидронафталин-1-ил-мочевины и их применение в лечении, среди прочего, заболеваний дыхательного тракта |
| CA2860095A1 (fr) | 2011-12-23 | 2013-06-27 | Cellzome Limited | Derives de pyrimidine-2,4-diamine en tant qu'inhibiteurs de kinase |
| CN103655577A (zh) * | 2012-09-20 | 2014-03-26 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN103664957A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN105130907B (zh) * | 2015-07-29 | 2018-10-16 | 沈阳药科大学 | 嘧啶类化合物及其用途 |
| DK3484528T3 (da) | 2016-07-18 | 2021-02-15 | Janssen Pharmaceutica Nv | Tau-pet-billeddannelsesligander |
| WO2020023851A1 (fr) * | 2018-07-26 | 2020-01-30 | Yale University | Pyrimidines substituées bifonctionnelles en tant que modulateurs du protéolyse de fak |
| US20240025887A1 (en) * | 2021-01-07 | 2024-01-25 | Ontario Institute For Cancer Research (Oicr) | Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
| CA3204401A1 (fr) * | 2021-01-07 | 2022-07-14 | Rima AL-AWAR | Composes d'aminopyrimidine d'isoindolinone en tant qu'inhibiteurs de kinases nuak, leurs compositions et utilisations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| WO2003030909A1 (fr) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| AU2003231231A1 (en) | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| RS20050363A (sr) | 2002-11-28 | 2007-11-15 | Schering Aktiengesellschaft, | Chk-,Pdk- I Akt-INHIBITORNI PIRIMIDINI, NJIHOVA PROIZVODNJA I UPOTREBA KAO FARMACEUTSKIH SREDSTAVA |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| EP1590334B1 (fr) | 2003-01-30 | 2009-08-19 | Boehringer Ingelheim Pharmaceuticals Inc. | Derives de 2,4-diaminopyrimidine utiles en tant qu'inhibiteurs de l'enzyme pkc-theta |
| MXPA06013165A (es) | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. |
| BRPI0511138A (pt) * | 2004-05-14 | 2007-11-27 | Pfizer Prod Inc | derivados de pirimidina para o tratamento de desenvolvimento celular anormal |
-
2006
- 2006-12-11 AU AU2006327871A patent/AU2006327871A1/en not_active Abandoned
- 2006-12-11 EA EA200801287A patent/EA014551B1/ru not_active IP Right Cessation
- 2006-12-11 JP JP2008546669A patent/JP4332590B2/ja not_active Expired - Fee Related
- 2006-12-11 CA CA2634646A patent/CA2634646C/fr not_active Expired - Fee Related
- 2006-12-11 WO PCT/IB2006/003655 patent/WO2007072158A2/fr not_active Ceased
- 2006-12-11 ME MEP-09/08A patent/MEP0908A/xx unknown
- 2006-12-11 EP EP06831737A patent/EP1966207A2/fr not_active Withdrawn
- 2006-12-11 AP AP2008004488A patent/AP2008004488A0/xx unknown
- 2006-12-11 BR BRPI0620324-8A patent/BRPI0620324A2/pt not_active IP Right Cessation
- 2006-12-11 KR KR1020087017637A patent/KR101060051B1/ko not_active Expired - Fee Related
- 2006-12-11 CN CN2006800487340A patent/CN101346380B/zh not_active Expired - Fee Related
- 2006-12-11 RS RSP-2008/0272A patent/RS20080272A/sr unknown
- 2006-12-11 UA UAA200807169A patent/UA89123C2/ru unknown
- 2006-12-14 NL NL2000375A patent/NL2000375C2/nl not_active IP Right Cessation
- 2006-12-19 DO DO2006000289A patent/DOP2006000289A/es unknown
- 2006-12-19 GT GT200600517A patent/GT200600517A/es unknown
- 2006-12-20 PE PE2006001661A patent/PE20071138A1/es not_active Application Discontinuation
- 2006-12-20 AR ARP060105660A patent/AR058399A1/es not_active Application Discontinuation
- 2006-12-20 HN HN2006042221A patent/HN2006042221A/es unknown
- 2006-12-20 TW TW095147907A patent/TW200736258A/zh unknown
- 2006-12-20 US US11/613,390 patent/US7820648B2/en not_active Expired - Fee Related
- 2006-12-21 UY UY30051A patent/UY30051A1/es not_active Application Discontinuation
-
2008
- 2008-05-19 IL IL191555A patent/IL191555A0/en unknown
- 2008-05-22 NO NO20082338A patent/NO20082338L/no not_active Application Discontinuation
- 2008-05-23 ZA ZA200804488A patent/ZA200804488B/xx unknown
- 2008-06-19 EC EC2008008563A patent/ECSP088563A/es unknown
- 2008-06-20 MA MA31059A patent/MA30075B1/fr unknown
- 2008-06-20 TN TNP2008000270A patent/TNSN08270A1/fr unknown
- 2008-06-20 SV SV2008002969A patent/SV2008002969A/es not_active Application Discontinuation
- 2008-06-20 CR CR10095A patent/CR10095A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30075B1 (fr) | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
| TN2009000544A1 (fr) | Derives de benzimidazole | |
| TN2009000428A1 (fr) | Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
| MA67365B1 (fr) | Dérivés de benzisoxazole sulfonamide | |
| MA29926B1 (fr) | Derives de pyrazine | |
| TNSN07022A1 (fr) | Derives de pyridine | |
| MA27754A1 (fr) | Pyrimidinones substituees | |
| MA30403B1 (fr) | Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques | |
| MA27389A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
| TW200607801A (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| WO2005037825A3 (fr) | Inhibiteurs de la proteine kinase | |
| MA27568A1 (fr) | Derives de pyrrolopyrimidine | |
| TW200612949A (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| TN2009000450A1 (fr) | Derives de pyridine | |
| TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
| TNSN04156A1 (fr) | Pyridinones substituees servant de modulateurs de la map-kinase p38 | |
| WO2004037181A3 (fr) | Inhibiteurs de dipeptidyl peptidase iv a base de glycinenitrile et procedes correspondants | |
| MA31873B1 (fr) | Inhibiteurs de la peptide déformylase | |
| MA32009B1 (fr) | Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux | |
| MXPA06013164A (es) | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. | |
| MA27775A1 (fr) | Composes organiques | |
| TNSN06370A1 (fr) | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
| TNSN07400A1 (fr) | Derives d'aminoacides | |
| MA27716A1 (fr) | 4-aminopyrimidine-5-one | |
| MA27930A1 (fr) | Derives de nicotinamide utiles comme inhibiteurs de pde4 |